Influenza Hemagglutinin (HA) Peptide: High-Purity Tag for Protein Detection and Purification

Executive Summary: The Influenza Hemagglutinin (HA) Peptide (sequence: YPYDVPDYA) is a synthetic epitope tag derived from influenza virus hemagglutinin, used extensively in protein detection and purification workflows (APExBIO A6004 product page). This peptide exhibits high solubility (≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, ≥46.2 mg/mL in water) and is supplied at >98% purity, confirmed by HPLC and mass spectrometry. It enables efficient immunoprecipitation and elution of HA-tagged fusion proteins by competitively binding anti-HA antibodies. Storage at -20°C in desiccated form preserves stability; long-term storage of peptide solutions is not recommended [Benchmarking article]. The HA tag system is widely validated for reproducibility in protein-protein interaction and ubiquitination research (Dong et al., 2025).

Biological Rationale

The HA tag peptide originated from the human influenza virus hemagglutinin protein, specifically the epitope region recognized by monoclonal antibody 12CA5 [Benchmarking article]. Its nine-amino acid sequence (YPYDVPDYA) allows it to be fused to recombinant proteins without significantly altering protein function or structure. The HA tag system enables precise isolation and detection of proteins in complex biological samples, facilitating studies of protein-protein interactions, posttranslational modifications, and cellular localization (Dong et al., 2025). Compared to larger tags, the HA peptide’s small size minimizes steric hindrance and preserves target protein activity [Advanced applications article].

Mechanism of Action of Influenza Hemagglutinin (HA) Peptide

The HA peptide tag functions as an epitope for high-affinity monoclonal antibodies, most commonly anti-HA clone 12CA5. When fused to a target protein, it enables specific recognition and binding by anti-HA antibodies in immunoprecipitation, Western blot, and immunofluorescence assays. For protein purification, the synthetic HA peptide is used to competitively elute HA-tagged proteins from antibody-bound matrices, such as Anti-HA Magnetic Beads. This competitive binding displaces the HA-tagged protein from the antibody, allowing its recovery in native or denaturing conditions (APExBIO A6004). The competitive interaction is reversible, facilitating gentle elution and preserving protein conformation for downstream analyses [Precision Tag article].

Evidence & Benchmarks

• HA peptide (YPYDVPDYA) is recognized with nanomolar affinity by anti-HA monoclonal antibody 12CA5, enabling sensitive detection and purification (Dong et al., 2025).
• APExBIO's HA peptide (A6004) demonstrates solubility values of ≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, and ≥46.2 mg/mL in water, supporting diverse buffer compatibility (APExBIO A6004).
• The peptide is validated at >98% purity by HPLC and mass spectrometry, ensuring batch-to-batch reproducibility in experimental workflows (APExBIO A6004).
• Use of HA peptide in immunoprecipitation and protein interaction studies is standardized in colorectal cancer research and E3 ligase–mediated ubiquitination analyses (Dong et al., 2025).
• Optimal peptide storage is desiccated at -20°C; solutions are stable short-term but degrade upon long-term storage, as shown in stability assays [Benchmarking article].

This article extends previous benchmarking by providing detailed mechanistic and workflow integration data, and clarifies the boundaries of HA peptide reliability compared to advanced tag application articles and scenario-driven immunoprecipitation guides.

Applications, Limits & Misconceptions

The Influenza Hemagglutinin (HA) Peptide is a versatile molecular biology tag with broad applications:

• Detection and quantification of HA-tagged proteins in Western blot, ELISA, and immunofluorescence assays.
• Purification and gentle elution of HA fusion proteins from antibody-based affinity matrices.
• Protein-protein interaction and ubiquitination studies, such as identification of E3 ligase substrates in cancer research (Dong et al., 2025).
• Compatibility with standard molecular biology workflows, including exosome biology and advanced proteomics [Exosome strategies article].

Common Pitfalls or Misconceptions

• The HA peptide does not bind directly to proteins or matrices—its function requires anti-HA antibody mediation.
• It is not suitable for in vivo therapeutic applications due to immunogenicity and lack of pharmacological validation.
• Incorrect storage (e.g., repeated freeze-thaw or non-desiccated conditions) leads to peptide degradation and loss of activity.
• The HA tag sequence is not universal for all species—antibody specificity may vary in non-mammalian systems.
• Long-term storage of peptide solutions (even at -20°C) is not recommended; reconstitute fresh aliquots as needed.

Workflow Integration & Parameters

The HA peptide (A6004) from APExBIO integrates into standard and advanced molecular workflows. For immunoprecipitation, recommended working solutions are prepared at 1–5 mg/mL in compatible buffers (e.g., PBS, Tris-HCl), with elution typically achieved at 0.1–1 mg/mL peptide concentration. High solubility allows direct dilution without precipitation. The tag is compatible with both magnetic bead and agarose-based matrices. For detection, anti-HA antibodies (monoclonal clone 12CA5 or equivalent) are used at manufacturer-recommended dilutions.

Storage guidelines are critical: lyophilized peptide should be kept at -20°C, desiccated, and protected from light. Avoid repeated freeze-thaw cycles; prepare fresh working solutions immediately before use. The product’s >98% purity ensures minimal off-target effects and reproducible results, supporting quantitative workflows in both research and diagnostic settings.

Conclusion & Outlook

The Influenza Hemagglutinin (HA) Peptide is a validated, high-purity molecular tag that underpins reliable protein detection and purification workflows in molecular biology. APExBIO’s A6004 peptide offers benchmark solubility and purity, facilitating reproducible results in protein interaction, ubiquitination, and advanced proteomics research. Future developments may include engineered HA tag variants with enhanced antibody specificity or reduced immunogenicity for specialized applications. For details on ordering and technical specifications, see the APExBIO Influenza Hemagglutinin (HA) Peptide product page.